Early de novo neoplasia after renal transplantation

The chronic use of immunosuppressive therapy in transplant recipients to prevent acute rejection increases the long-term risk of cancer. The overall incidence of de novo malignancies (DNM) after kidney transplantation ranges from 6% to 11%. Between January 2000 and December 2002, 135 renal and 3 com...

Full description

Saved in:
Bibliographic Details
Published inTumori Vol. 89; no. 4 Suppl; p. 301
Main Authors Veroux, P, Veroux, M, Puliatti, C, Amodeo, C, Macarone, M, Cappello, D, Caglià, P
Format Journal Article
LanguageItalian
Published United States 01.07.2003
Subjects
Adolescent
Adult
Female
Graft Rejection
Humans
Immunocompromised Host
Immunosuppression - adverse effects
Immunosuppressive Agents - adverse effects
Incidence
Italy - epidemiology
Kidney Transplantation
Male
Middle Aged
Neoplasms - epidemiology
Neoplasms - etiology
Postoperative Complications - epidemiology
Postoperative Complications - etiology
Retrospective Studies
Italy
Online AccessGet more information

Cover

More Information
Summary:The chronic use of immunosuppressive therapy in transplant recipients to prevent acute rejection increases the long-term risk of cancer. The overall incidence of de novo malignancies (DNM) after kidney transplantation ranges from 6% to 11%. Between January 2000 and December 2002, 135 renal and 3 combined kidney-pancreas transplantations were performed. Of 138 solid organ transplant recipients, a total of 16 (11.6%) cancers were diagnosed in 10 renal transplant recipients (7.2%). Six patients were male and three female, with a mean age of 47 years (range, 19-63, years). Tumor presented at a mean time of 14 months (range, 2-24, months) after transplantation. There were three patients with skin cancers, three with Kaposis's sarcoma, one with renal cell cancer, one with bladder carcinoma and one with breast cancer. Although the DNM occurs more frequently many years after a kidney transplantation, our experience demonstrated that they can occur early in the follow-up. Skin malignancies had the best prognosis, probably because of early detection and treatment. Kaposi's sarcoma benefits from reduction or cessation of immuno-suppression, but there is a higher risk of graft loss. Solid organ de novo malignancies are often more aggressive than in normal population, and the life expectancy of these recipients is very low. Careful long-term screening protocols are needed for detection of such malignancies in an early stage.
ISSN:0300-8916